The HCPLive uveitis page is a comprehensive resource for clinical news and insights on chorioretinitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for eye inflammation, and more.
October 20th 2024
TRS01 eye drops demonstrate a positive benefit-risk profile for potential use as a first-line treatment in anterior non-infectious uveitis.
Tubulointerstitial Nephritis and Uveitis Syndrome Threatens Vision in Some Patients
Some cases of tubulointerstitial nephritis and uveitis syndrome, or TINU, have a poor visual prognosis, so early diagnosis and treatment are recommended. Diagnosis requires detailed history taking, whole-body imaging studies, and examination of renal function.
Sirolimus Showed Improvements in Patients with Active Noninfectious Posterior Uveitis
In the SAKURA study, a greater proportion of those in the intravitreal sirolimus treatment groups than those in the active control group met the primary endpoint, a vitreous haze score of zero at Month 5 without the use of rescue therapy.
For Bilateral Uveitic Glaucoma, It May be Best to Operate on Second Eye Sooner than Later
A retrospective review of patients with bilateral uveitic glaucoma who had filtration surgery in both eyes at different times found that the second surgically treated eye showed greater glaucomatous disc progression than the first.
Antibody Development an Obstacle in Treating Uveitis with Humira
A Spanish research team found an association between testing positive for antibodies to adalimumab (Humira) and a worse outcome of uveitis, but only in those who tested positive permanently. They also found that this association correlated with undetectable trough levels of Humira.
Uveitis: Pediatric Patients Did Fine on Adalimumab
Adalimumab has the potential to serve an important role in management of chronic and refractory noninfectious uveitis and associated macular edema with low rates of serious adverse events in the long term, according to a recent report. That includes pediatric patients.
Immunosuppressants Help Extend Treatment Effect in Uveitis
Adalimumab (ADA) works well as a treatment for patients with both active and inactive uveitis whether or not they are taking an immunosuppressant (IMM); however, the median time to treatment failure (mTTF) is longer for patients with inactive uveitis taking an IMM.
Women With Spondyloarthritis Face Increased Risk of Uveitis, Other Conditions
A new study out of Ireland examined the prevalence of extra-articular manifestations in axial spondyloarthritis, and found that women were at significantly higher risk for inflammatory bowel disease and uveitis than men.
Estimating the Prevalence of Noninfectious Uveitis with a Massive Claims Database
The prevalence of noninfectious uveitis was 121 cases per 100,000 adults and 29 cases per 100,000 children. By such estimates, nearly 300,000 adults and 22,000 children in the United States had the disease in 2015.